metformin has been researched along with Hyperlipidemias in 100 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Hyperlipidemias: Conditions with excess LIPIDS in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia." | 9.19 | Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014) |
| "The objective of this study was to examine the effect of the antihyperglycemic agents metformin (insulin sensitizer) and glibenclamide (insulin secretory agent) on the serum level of C-reactive protein (CRP) in well-controlled type 2 diabetics with metabolic syndrome." | 9.10 | Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. ( Akbar, DH, 2003) |
| "The endocrine-metabolic status of non-obese, young women with polycystic ovary syndrome (PCOS) is normalized more effectively by combined treatment with flutamide and metformin than by either of these drugs in monotherapy." | 9.10 | Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. ( de Zegher, F; Ibáñez, L, 2003) |
| "Metformin given for 12 weeks as a supplement to lovastatin, diet and lifestyle advice to non-diabetic male patients with coronary heart disease further improves the lipid pattern in normal weight patients, and reduces weight in the overweight patients." | 9.08 | Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. ( Bjerve, KS; Carlsen, SM; Følling, I; Rossvoll, O, 1996) |
| "The present study aimed to investigate the effect of metformin on diabetes-accelerated atherosclerosis and whether Nod-like receptor protein 3 (NLRP3) inflammasome is a target for metformin." | 7.91 | Metformin inhibited Nod-like receptor protein 3 inflammasomes activation and suppressed diabetes-accelerated atherosclerosis in apoE ( Chen, Y; Duan, F; Hu, J; Li, H; Li, W; Tan, H; Tang, G; Wang, Y; Zeng, C; Zhang, X, 2019) |
| "Metformin and rosuvastatin combination therapy could lead to a better reduction on hyperandrogenism and on atherosclerosis-related factors in PCOS, in addition to improving lipid parameters." | 7.78 | Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. ( Acbay, O; Celik, O, 2012) |
| "To determine whether improvement of insulin resistance decreases blood pressure as well as obesity, metformin (100 mg/kg/d) or vehicle was administered for 20 weeks to 12-week-old male Otsuka Long-Evans Tokushima Fatty (OLETF) rats (n = 10 each), a newly developed animal model of non-insulin-dependent diabetes mellitus (NIDDM) with mild obesity, hyperinsulinemia, and hypertriglyceridemia." | 7.69 | Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. ( Inukai, K; Ishii, J; Kashiwabara, H; Katayama, S; Kikuchi, C; Kosegawa, I; Negishi, K; Oka, Y, 1996) |
| "Metformin was well tolerated and no one discontinued treatment due to side effects." | 6.70 | Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. ( Grinspoon, S; Hadigan, C; Rabe, J, 2002) |
| "Metformin (Met) is an antidiabetic drug with beneficial cardiovascular disease effects." | 5.62 | Metformin attenuates hyperlipidaemia-associated vascular calcification through anti-ferroptotic effects. ( Liu, NF; Ma, WQ; Sun, XJ; Zhu, Y, 2021) |
| "To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia." | 5.19 | Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014) |
| "Rosiglitazone improved insulin sensitivity and decreased postprandial hydroxybutyric acid levels in patients with HIV-lipodystrophy, suggesting improved FFA handling." | 5.15 | Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy. ( Cabezas, MC; Dallinga-Thie, G; de Koning, EJ; Hoepelman, AI; Rabelink, TJ; van Wijk, JP, 2011) |
| "The endocrine-metabolic status of non-obese, young women with polycystic ovary syndrome (PCOS) is normalized more effectively by combined treatment with flutamide and metformin than by either of these drugs in monotherapy." | 5.10 | Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. ( de Zegher, F; Ibáñez, L, 2003) |
| "The objective of this study was to examine the effect of the antihyperglycemic agents metformin (insulin sensitizer) and glibenclamide (insulin secretory agent) on the serum level of C-reactive protein (CRP) in well-controlled type 2 diabetics with metabolic syndrome." | 5.10 | Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. ( Akbar, DH, 2003) |
| "In type 2 diabetic patients, the vasodilating response to forearm ischemia was the same whether patients were treated with diet treatment alone or with glibenclamide or glimepiride at blood glucose-lowering equipotent closes." | 5.09 | Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia. ( Brunelli, C; Cordera, R; Cordone, S; Olivotti, L; Rossettin, P; Schiavo, M; Spallarossa, P, 2001) |
| "Metformin given for 12 weeks as a supplement to lovastatin, diet and lifestyle advice to non-diabetic male patients with coronary heart disease further improves the lipid pattern in normal weight patients, and reduces weight in the overweight patients." | 5.08 | Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. ( Bjerve, KS; Carlsen, SM; Følling, I; Rossvoll, O, 1996) |
| " Metformin is currently the preferred insulin-sensitizing drug for chronic treatment of PCOS and has been shown to improve the metabolic profile, menstrual cyclicity and fertility in women with PCOS, and is associated with weight loss." | 4.85 | Polycystic ovary syndrome and metabolic comorbidities: therapeutic options. ( De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC; Palermo, V; Petraglia, F, 2009) |
| " Search terms used were insulin resistance, diabetes, insulin sensitivity, obesity, cardiovascular disease, metformin, thiazolidinediones, pioglitazone, rosiglitazone, and troglitazone." | 4.82 | Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. ( Henry, RR, 2003) |
| " Although no clinical trials over 6 months in duration have assessed the long-term efficacy of metformin use in adolescents, short-term trials have shown promising effects in lowering insulin secretion, improving insulin sensitivity, restoring normal menstrual cycles, and correcting lipid abnormalities." | 4.81 | Polycystic ovary syndrome in adolescents. ( Kent, SC; Legro, RS, 2002) |
| " Metformin and troglitazone, approved for use in the treatment of type 2 diabetes mellitus (DM), improve insulin sensitivity and lower plasma glucose concentrations." | 4.80 | Insulin resistance syndrome: options for treatment. ( Fonseca, VA; Granberry, MC, 1999) |
| " Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure." | 4.79 | [Treatment of hypertension associated with diabetes mellitus]. ( Katayama, S, 1997) |
| "While this class of drugs holds great promise for cases of refractory hyperinsulinemia and laminitis that do not respond to diet or metformin therapy, hypertriglyceridemia is a potential side effect." | 4.31 | Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors. ( Gustafson, KM; Kellon, EM, 2023) |
| "PSO and metformin had the beneficial effect on attenuating gut inflammation and metabolic disturbance in obese-insulin resistance." | 4.02 | Perilla Seed Oil Alleviates Gut Dysbiosis, Intestinal Inflammation and Metabolic Disturbance in Obese-Insulin-Resistant Rats. ( Chattipakorn, N; Chattipakorn, SC; Kangwan, N; Kongkaew, A; Pintha, K; Pratchayasakul, W, 2021) |
| "Treatment with the polyherbal mixture extract was more effective than the standard drugs (insulin and metformin) in the amelioration of hyperglycemia, hyperlipidemia, and histopathological changes of the pancreas, kidney and liver tissue." | 4.02 | Polyherbal mixture ameliorates hyperglycemia, hyperlipidemia and histopathological changes of pancreas, kidney and liver in a rat model of type 1 diabetes. ( Djordjević, L; Jugović, D; Jušković, M; Madić, V; Petrović, A; Stojanović, G; Vasiljević, P, 2021) |
| "The present study aimed to investigate the effect of metformin on diabetes-accelerated atherosclerosis and whether Nod-like receptor protein 3 (NLRP3) inflammasome is a target for metformin." | 3.91 | Metformin inhibited Nod-like receptor protein 3 inflammasomes activation and suppressed diabetes-accelerated atherosclerosis in apoE ( Chen, Y; Duan, F; Hu, J; Li, H; Li, W; Tan, H; Tang, G; Wang, Y; Zeng, C; Zhang, X, 2019) |
| " Compared with vehicle-treated mice, borapetoside E markedly improved hyperglycemia, insulin resistance, hepatic steatosis, hyperlipidemia, and oxygen consumption in obese mice, and the effects were comparable to or better than the drug metformin." | 3.85 | Borapetoside E, a Clerodane Diterpenoid Extracted from Tinospora crispa, Improves Hyperglycemia and Hyperlipidemia in High-Fat-Diet-Induced Type 2 Diabetes Mice. ( Gao, Y; Hu, J; Liu, J; Lu, Y; Niu, Y; Peng, L; Qin, W; Wang, F; Xiong, W; Xu, Y, 2017) |
| "Metformin and rosuvastatin combination therapy could lead to a better reduction on hyperandrogenism and on atherosclerosis-related factors in PCOS, in addition to improving lipid parameters." | 3.78 | Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. ( Acbay, O; Celik, O, 2012) |
| "To determine whether improvement of insulin resistance decreases blood pressure as well as obesity, metformin (100 mg/kg/d) or vehicle was administered for 20 weeks to 12-week-old male Otsuka Long-Evans Tokushima Fatty (OLETF) rats (n = 10 each), a newly developed animal model of non-insulin-dependent diabetes mellitus (NIDDM) with mild obesity, hyperinsulinemia, and hypertriglyceridemia." | 3.69 | Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. ( Inukai, K; Ishii, J; Kashiwabara, H; Katayama, S; Kikuchi, C; Kosegawa, I; Negishi, K; Oka, Y, 1996) |
| "Lowering postprandial lipemia may mitigate cardiovascular risk in patients with diabetic dyslipidemia." | 2.94 | Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study. ( Bhatt, J; Dunbar, RL; Parmar, DV; Parmar, K; Rastogi, A; Thacker, HP, 2020) |
| "Postprandial hyperlipidaemia in type 2 diabetes is secondary to increased chylomicron production by the enterocytes and delayed catabolism of chylomicrons and chylomicron remnants." | 2.82 | Intestinal lipid absorption and transport in type 2 diabetes. ( Vergès, B, 2022) |
| "Despite the increasing prevalence of type 2 diabetes mellitus (T2DM) in Asia, clinical trials for glucose-lowering therapies are often dominated by Caucasian and/or Western populations." | 2.82 | Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial. ( Gong, Y; Izumoto, T; Ning, G; Patel, S; Wang, W; Yang, G; Yang, J; Zhang, C, 2016) |
| "Both repaglinide and metformin were effective in glycaemic control in new onset patients with type 2 diabetes in China." | 2.79 | Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China. ( Liao, Y; Liu, LY; Liu, W; Ma, J; Tao, T; Wu, PH, 2014) |
| "Diabetes mellitus type 2 with dyslipidemia is a common disease." | 2.77 | Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. ( Dabaghian, FH; Hajiaghaee, R; Huseini, HF; Kianbakht, S, 2012) |
| "Metformin was well tolerated and no one discontinued treatment due to side effects." | 2.70 | Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. ( Grinspoon, S; Hadigan, C; Rabe, J, 2002) |
| "We hypothesized that dyslipidemia and anovulation in nonobese women with polycystic ovary syndrome are essentially secondary to the concerted effects of hyperandrogenism and insulin resistance." | 2.70 | Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. ( De Zegher, F; Dunger, DB; Ferrer, A; Ibáñez, L; Ong, K; Valls, C, 2002) |
| "Metformin treatment was well tolerated and was accompanied by a marked drop in hirsutism score, insulin response to oral glucose tolerance test, free androgen index, and baseline testosterone, androstenedione, dehydroepiandrosterone, and dehydroepiandrosterone sulfate levels (all P < 0." | 2.69 | Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. ( de Zegher, F; Ibáñez, L; Marcos, MV; Potau, N; Valls, C, 2000) |
| " The patients were randomly given metformin in two dosage levels (1." | 2.67 | Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial. ( Aro, A; Pentikäinen, PJ; Penttilä, I; Uusitupa, M; Vapaatalo, H; Voutilainen, E, 1990) |
| "Overall, 7% of the US population has type 2 diabetes mellitus (T2DM), and among people aged 60 years or older, approximately 20% have T2DM, representing a significant health burden in this age group." | 2.44 | Initiating insulin in patients with type 2 diabetes. ( Aoki, TJ; White, RD, 2007) |
| "Patients with type 2 diabetes have an increased risk for cardiovascular disease (CVD) and it accounts for up to 80% of excess deaths in these patients." | 2.42 | Role of oral anti-diabetic agents in modifying cardiovascular risk factors. ( Farag, A; McFarlane, SI; Rothman, J; Shin, JJ; Sowers, JR, 2003) |
| "Insulin resistance is a condition in which the glycemic response to insulin is less than normal." | 2.42 | Treatment of insulin resistance in diabetes mellitus. ( Banerji, MA; Lebovitz, HE, 2004) |
| "Obesity is an increasingly prevalent problem with many associated health risks." | 2.42 | Hepatotoxicity of drugs used for treatment of obesity and its comorbidities. ( Ghali, P; Lindor, KD, 2004) |
| "Type 2 diabetes is the most prevalent form of diabetes, accounting for approximately 90% of cases." | 2.41 | Management of type 2 diabetes. Evolving strategies for treatment. ( Kitabchi, AE; Umpierrez, GE, 2001) |
| "The characteristic dyslipidemia of insulin resistance consists of elevated triglyceride and triglyceride-rich lipoprotein levels, low levels of high-density lipoprotein cholesterol, and increased concentrations of small, dense low-density lipoprotein cholesterol." | 2.41 | Pathophysiology and treatment of the dyslipidemia of insulin resistance. ( Capuzzi , DM; Cohn, G; Valdes, G, 2001) |
| " However, as the two agents have very different chemical structure and bioavailability in oral route, the goal of this study is to learn their characteristics in treating metabolic disorders." | 1.91 | Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases. ( Gao, TL; Guo, HH; Han, YX; Jiang, JD; Luo, ZG; Shen, HR; Wang, LL; Zhang, HJ; Zhang, JL, 2023) |
| "Metformin (Met) is an antidiabetic drug with beneficial cardiovascular disease effects." | 1.62 | Metformin attenuates hyperlipidaemia-associated vascular calcification through anti-ferroptotic effects. ( Liu, NF; Ma, WQ; Sun, XJ; Zhu, Y, 2021) |
| "Hypertension (60." | 1.56 | Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. ( Bachmann, KN; Bradford, R; Buse, JB; Chakkalakal, RJ; Choi, S; Cook, MM; Dard, S; Donahoo, WT; Fanous, N; Fonseca, V; Grijalva, CG; Katalenich, B; Knoepp, P; Louzao, D; Morris, HL; O'Brien, E; Rothman, RL; Roumie, CL; Wiese, AD; Zalimeni, EO, 2020) |
| " Moreover, the Cmax of pseudo-germ-free rats increased significantly, while the t1/2α decreased significantly." | 1.51 | In vivo pharmacodynamic and pharmacokinetic effects of metformin mediated by the gut microbiota in rats. ( Chen, M; Gao, Y; Hu, J; Huang, W; Liu, M; Wu, B; Zhang, W, 2019) |
| "Hyperlipidemia by itself did not affect the pharmacokinetics of metformin." | 1.46 | Pharmacokinetics of metformin in the rat: assessment of the effect of hyperlipidemia and evidence for its metabolism to guanylurea. ( Ben-Eltriki, M; Brocks, DR; El-Kadi, AO; El-Sherbeni, AA; Gabr, RQ, 2017) |
| "Hyperlipidemia was protective against hepatocellular carcinoma (OR 0." | 1.46 | Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. ( Kasmari, AJ; Leslie, D; Liu, G; McGarrity, T; Riley, T; Welch, A, 2017) |
| "Metformin is a strong candidate to be incorporated in alternative therapeutic approaches." | 1.46 | Metformin Potentiates the Benefits of Dietary Restraint: A Metabolomic Study. ( Cabré, N; Camps, J; Cuyàs, E; Fernández-Arroyo, S; García-Heredia, A; Hernández-Aguilera, A; Joven, J; Luciano-Mateo, F; Menendez, JA; Riera-Borrull, M, 2017) |
| " The metforminium decavanadate (H2Metf)3[V10O28]·8H2O, abbreviated as Metf-V10O28, was shown to have pharmacological potential as a hypoglycemic, lipid-lowering and metabolic regulator, since the resulting compound made of the two components with antidiabetic activities, reduces both dosage and time of administration (twice a week)." | 1.42 | Hypoglycemic, lipid-lowering and metabolic regulation activities of metforminium decavanadate (H2Metf)3 [V10O28]·8H2O using hypercaloric-induced carbohydrate and lipid deregulation in Wistar rats as biological model. ( Brambila-Colombres, E; Flores-Hernández, JÁ; González-Vergara, E; Pérez-Benítez, A; Sánchez-Lara, E; Sánchez-Lombardo, I; Sarmiento-Ortega, VE; Treviño, S, 2015) |
| "Hyperglycemia and hyperlipidemia directly affected the contractile function of VSMCs." | 1.42 | Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway. ( Chen, XY; Lan, D; Li, T; Liu, LM; Tian, KL; Wu, Y; Yang, GM; Zhu, Y, 2015) |
| "Semecarpus anacardium nut milk extract at a dosage of 200 mg/kg orally significantly (p < 0." | 1.39 | Anti-inflammatory and anti-hyperlipidemic effect of Semecarpus anacardium in a high fat diet: STZ-induced type 2 diabetic rat model. ( Khan, HB; Moorthy, BT; Palanivelu, S; Panchanatham, S; Vinayagam, KS, 2013) |
| "Diabetic hyperlipidemia was simulated in this cell system by addition of the fatty acid palmitate." | 1.38 | Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells. ( Holst, JJ; Kappe, C; Sjöholm, A; Zhang, Q, 2012) |
| "Metformin pre-treatment also reduced endothelial cell damage in ferrous chloride induced thrombosis in carotid arteries." | 1.37 | Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats. ( Bhadada, SV; Dhamecha, PS; Ghatak, SB; Panchal, SJ, 2011) |
| "hepatic complications of type 2 diabetes with hyperlipidaemia and the effects of atorvastatin and metformin, isolated and in association, in systemic and hepatic inflammatory and oxidative stress markers were tested using genetic type 2 diabetic Goto-Kakizaki rats fed with a high-fat diet." | 1.37 | Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. ( Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R, 2011) |
| "Felodipine was withdrawn and the diabetes was controlled before dental treatment was initiated." | 1.33 | Felodipine-influenced gingival enlargement in an uncontrolled type 2 diabetic patient. ( Fay, AA; Gapski, R; Satheesh, K, 2005) |
| "Because both type 2 diabetes and elevated plasma lipid levels are important independent risk factors for cardiovascular disease and coronary heart disease, the choice of an antihyperglycemic agent for patients with type 2 diabetes--in whom abnormal plasma lipid levels are often seen-should take into account effects on lipids as well as on markers of glycemic control." | 1.31 | Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study. ( Dailey, GE; Fiedorek, FT; Mohideen, P, 2002) |
"Metformin treatment was accompanied by a drop in fasting insulin and serum androgens and by a less atherogenic lipid profile (all P | 1.31 | Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. ( De Zegher, F; Ferrer, A; Ibáñez, L; Marcos, MV; Potau, N; Rodriguez-Hierro, F, 2002) | |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (13.00) | 18.7374 |
| 1990's | 10 (10.00) | 18.2507 |
| 2000's | 31 (31.00) | 29.6817 |
| 2010's | 35 (35.00) | 24.3611 |
| 2020's | 11 (11.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, Y | 2 |
| Niu, Y | 1 |
| Gao, Y | 2 |
| Wang, F | 1 |
| Qin, W | 1 |
| Lu, Y | 1 |
| Hu, J | 3 |
| Peng, L | 1 |
| Liu, J | 2 |
| Xiong, W | 1 |
| Zahran, F | 1 |
| Mohamad, A | 1 |
| Zein, N | 1 |
| Kangwan, N | 1 |
| Pratchayasakul, W | 1 |
| Kongkaew, A | 1 |
| Pintha, K | 1 |
| Chattipakorn, N | 1 |
| Chattipakorn, SC | 1 |
| Vergès, B | 1 |
| Kellon, EM | 1 |
| Gustafson, KM | 1 |
| Guo, HH | 1 |
| Shen, HR | 1 |
| Wang, LL | 1 |
| Luo, ZG | 1 |
| Zhang, JL | 1 |
| Zhang, HJ | 1 |
| Gao, TL | 1 |
| Han, YX | 1 |
| Jiang, JD | 1 |
| Tang, G | 1 |
| Duan, F | 1 |
| Li, W | 1 |
| Wang, Y | 1 |
| Zeng, C | 1 |
| Li, H | 1 |
| Zhang, X | 1 |
| Chen, Y | 1 |
| Tan, H | 1 |
| Geberemeskel, GA | 1 |
| Debebe, YG | 1 |
| Nguse, NA | 1 |
| Luo, Y | 2 |
| Zhu, Y | 3 |
| Chen, J | 1 |
| Gao, X | 1 |
| Yang, W | 1 |
| Zou, X | 2 |
| Zhou, X | 1 |
| Ji, L | 1 |
| Rastogi, A | 1 |
| Dunbar, RL | 1 |
| Thacker, HP | 1 |
| Bhatt, J | 1 |
| Parmar, K | 1 |
| Parmar, DV | 1 |
| Madić, V | 1 |
| Petrović, A | 1 |
| Jušković, M | 1 |
| Jugović, D | 1 |
| Djordjević, L | 1 |
| Stojanović, G | 1 |
| Vasiljević, P | 1 |
| Bachmann, KN | 1 |
| Roumie, CL | 1 |
| Wiese, AD | 1 |
| Grijalva, CG | 1 |
| Buse, JB | 1 |
| Bradford, R | 1 |
| Zalimeni, EO | 1 |
| Knoepp, P | 1 |
| Dard, S | 1 |
| Morris, HL | 1 |
| Donahoo, WT | 1 |
| Fanous, N | 1 |
| Fonseca, V | 1 |
| Katalenich, B | 1 |
| Choi, S | 1 |
| Louzao, D | 1 |
| O'Brien, E | 1 |
| Cook, MM | 1 |
| Rothman, RL | 1 |
| Chakkalakal, RJ | 1 |
| Balvers, M | 1 |
| van den Born, BH | 1 |
| Levin, E | 1 |
| Nieuwdorp, M | 1 |
| Ma, WQ | 1 |
| Sun, XJ | 1 |
| Liu, NF | 1 |
| Hu, D | 1 |
| Guo, Y | 1 |
| Wu, R | 2 |
| Shao, T | 1 |
| Long, J | 1 |
| Yu, B | 1 |
| Wang, H | 1 |
| Lu, H | 1 |
| Zhang, J | 1 |
| Chen, YE | 1 |
| Peng, D | 1 |
| Skolnik, N | 1 |
| Jaffa, FM | 1 |
| Kalyani, RR | 1 |
| Johnson, E | 1 |
| Shubrook, JH | 1 |
| Riera-Borrull, M | 1 |
| García-Heredia, A | 1 |
| Fernández-Arroyo, S | 1 |
| Hernández-Aguilera, A | 1 |
| Cabré, N | 1 |
| Cuyàs, E | 1 |
| Luciano-Mateo, F | 1 |
| Camps, J | 1 |
| Menendez, JA | 1 |
| Joven, J | 1 |
| Tong, X | 1 |
| Xu, J | 1 |
| Lian, F | 1 |
| Yu, X | 1 |
| Zhao, Y | 1 |
| Xu, L | 1 |
| Zhang, M | 1 |
| Zhao, X | 1 |
| Shen, J | 1 |
| Wu, S | 1 |
| Pang, X | 1 |
| Tian, J | 1 |
| Zhang, C | 2 |
| Zhou, Q | 1 |
| Wang, L | 1 |
| Pang, B | 1 |
| Chen, F | 1 |
| Peng, Z | 1 |
| Wang, J | 1 |
| Zhen, Z | 1 |
| Fang, C | 1 |
| Li, M | 1 |
| Chen, L | 1 |
| Zhao, L | 1 |
| Jonnalagadda, VG | 1 |
| Shravan Kumar, U | 1 |
| Afsar, S | 1 |
| Liu, Y | 1 |
| Wang, C | 1 |
| Li, J | 1 |
| Mei, Y | 1 |
| Liang, Y | 1 |
| Wu, B | 1 |
| Chen, M | 1 |
| Liu, M | 1 |
| Zhang, W | 1 |
| Huang, W | 1 |
| Ma, J | 1 |
| Liu, LY | 1 |
| Wu, PH | 1 |
| Liao, Y | 1 |
| Tao, T | 1 |
| Liu, W | 1 |
| Derosa, G | 1 |
| Bonaventura, A | 1 |
| Bianchi, L | 1 |
| Romano, D | 1 |
| Fogari, E | 1 |
| D'Angelo, A | 1 |
| Maffioli, P | 1 |
| Li, T | 1 |
| Yang, GM | 1 |
| Wu, Y | 1 |
| Chen, XY | 1 |
| Lan, D | 1 |
| Tian, KL | 1 |
| Liu, LM | 1 |
| Wang, W | 1 |
| Yang, J | 1 |
| Yang, G | 1 |
| Gong, Y | 1 |
| Patel, S | 1 |
| Izumoto, T | 1 |
| Ning, G | 1 |
| Treviño, S | 1 |
| Sánchez-Lara, E | 1 |
| Sarmiento-Ortega, VE | 1 |
| Sánchez-Lombardo, I | 1 |
| Flores-Hernández, JÁ | 1 |
| Pérez-Benítez, A | 1 |
| Brambila-Colombres, E | 1 |
| González-Vergara, E | 1 |
| Regelmann, MO | 1 |
| Goldis, M | 1 |
| Arnon, R | 1 |
| Zonszein, J | 1 |
| Lombardero, M | 1 |
| Ismail-Beigi, F | 1 |
| Palumbo, P | 1 |
| Foucher, S | 1 |
| Groenewoud, Y | 1 |
| Cushing, G | 1 |
| Wajchenberg, B | 1 |
| Genuth, S | 1 |
| Jiang, SJ | 1 |
| Dong, H | 1 |
| Li, JB | 1 |
| Xu, LJ | 1 |
| Wang, KF | 1 |
| Lu, FE | 1 |
| Yi, P | 1 |
| McGinty, EE | 1 |
| Baller, J | 1 |
| Azrin, ST | 1 |
| Juliano-Bult, D | 1 |
| Daumit, GL | 1 |
| Fu, L | 1 |
| Bruckbauer, A | 1 |
| Li, F | 1 |
| Cao, Q | 1 |
| Cui, X | 1 |
| Shi, H | 1 |
| Zemel, MB | 1 |
| Xue, B | 1 |
| De Sousa, SM | 1 |
| Norman, RJ | 1 |
| Gujjala, S | 1 |
| Putakala, M | 1 |
| Ramaswamy, R | 1 |
| Desireddy, S | 1 |
| Kasmari, AJ | 1 |
| Welch, A | 1 |
| Liu, G | 1 |
| Leslie, D | 1 |
| McGarrity, T | 1 |
| Riley, T | 1 |
| Gabr, RQ | 1 |
| El-Sherbeni, AA | 1 |
| Ben-Eltriki, M | 1 |
| El-Kadi, AO | 1 |
| Brocks, DR | 1 |
| Aoki, TJ | 1 |
| White, RD | 1 |
| De Leo, V | 1 |
| Musacchio, MC | 1 |
| Palermo, V | 1 |
| Di Sabatino, A | 1 |
| Morgante, G | 1 |
| Petraglia, F | 1 |
| Ntaios, G | 1 |
| Savopoulos, C | 1 |
| Chatzopoulos, S | 1 |
| Mikhailidis, D | 1 |
| Hatzitolios, A | 1 |
| van Wijk, JP | 1 |
| Hoepelman, AI | 1 |
| de Koning, EJ | 1 |
| Dallinga-Thie, G | 1 |
| Rabelink, TJ | 1 |
| Cabezas, MC | 1 |
| Matafome, P | 1 |
| Louro, T | 1 |
| Rodrigues, L | 1 |
| Crisóstomo, J | 1 |
| Nunes, E | 1 |
| Amaral, C | 1 |
| Monteiro, P | 1 |
| Cipriano, A | 1 |
| Seiça, R | 1 |
| Ghatak, SB | 1 |
| Dhamecha, PS | 1 |
| Bhadada, SV | 1 |
| Panchal, SJ | 1 |
| Sharif, A | 1 |
| Chen, WL | 1 |
| Wei, HW | 1 |
| Chiu, WZ | 1 |
| Kang, CH | 1 |
| Lin, TH | 1 |
| Hung, CC | 1 |
| Chen, MC | 1 |
| Shieh, MS | 1 |
| Lee, CC | 1 |
| Lee, HM | 1 |
| Huseini, HF | 1 |
| Kianbakht, S | 1 |
| Hajiaghaee, R | 1 |
| Dabaghian, FH | 1 |
| Khan, HB | 1 |
| Vinayagam, KS | 1 |
| Moorthy, BT | 1 |
| Palanivelu, S | 1 |
| Panchanatham, S | 1 |
| Celik, O | 1 |
| Acbay, O | 1 |
| Kappe, C | 1 |
| Holst, JJ | 1 |
| Zhang, Q | 1 |
| Sjöholm, A | 1 |
| Chaiteerakij, R | 1 |
| Yang, JD | 1 |
| Harmsen, WS | 1 |
| Slettedahl, SW | 1 |
| Mettler, TA | 1 |
| Fredericksen, ZS | 1 |
| Kim, WR | 1 |
| Gores, GJ | 1 |
| Roberts, RO | 1 |
| Olson, JE | 1 |
| Therneau, TM | 1 |
| Roberts, LR | 1 |
| Hadigan, C | 1 |
| Rabe, J | 1 |
| Grinspoon, S | 1 |
| Dailey, GE | 1 |
| Mohideen, P | 1 |
| Fiedorek, FT | 1 |
| Serrano Rios, M | 1 |
| Ascaso Gimilio, JF | 1 |
| Blázquez Fernández, E | 1 |
| Cabezas Cerraro, J | 1 |
| Carmena Rodríguez, R | 1 |
| Escobar Jiménez, F | 1 |
| Fernández-Real, JM | 1 |
| Gabriel Sánchez, R | 1 |
| Gomis de Barberá, R | 1 |
| Grande Aragón, C | 1 |
| Herrera Pomba, JL | 1 |
| Pallardo Sánchez, LF | 1 |
| Potau Vilalta, N | 1 |
| Ricart Engel, W | 1 |
| Rovira Loscos, A | 1 |
| Zorzano Olarte, A | 1 |
| Ibáñez, L | 4 |
| Potau, N | 2 |
| Ferrer, A | 2 |
| Rodriguez-Hierro, F | 1 |
| Marcos, MV | 2 |
| De Zegher, F | 4 |
| Akbar, DH | 1 |
| Tuomilehto, J | 1 |
| Fonseca, VA | 2 |
| Henry, RR | 1 |
| Schröder, AK | 1 |
| Tauchert, S | 1 |
| Ortmann, O | 1 |
| Diedrich, K | 1 |
| Weiss, JM | 1 |
| Shin, JJ | 1 |
| Rothman, J | 1 |
| Farag, A | 1 |
| McFarlane, SI | 1 |
| Sowers, JR | 1 |
| Lebovitz, HE | 1 |
| Banerji, MA | 1 |
| Khan, M | 1 |
| Edwards, G | 1 |
| Urquhart, R | 1 |
| Mariz, S | 1 |
| Ghali, P | 1 |
| Lindor, KD | 1 |
| Kume, A | 1 |
| Miyazaki, T | 1 |
| Daida, H | 1 |
| Tran, HA | 1 |
| Chua, Y | 1 |
| Petrovsky, N | 1 |
| Lombard, L | 1 |
| Fay, AA | 1 |
| Satheesh, K | 1 |
| Gapski, R | 1 |
| Lynch, T | 1 |
| Wild, RA | 1 |
| Zavaroni, I | 1 |
| Dall'Aglio, E | 1 |
| Bruschi, F | 1 |
| Alpi, O | 1 |
| Coscelli, C | 1 |
| Butturini, U | 1 |
| Shen, ZF | 1 |
| Liu, HF | 1 |
| Ye, F | 1 |
| Xie, MZ | 1 |
| Grant, PJ | 1 |
| Carlsen, SM | 1 |
| Rossvoll, O | 1 |
| Bjerve, KS | 1 |
| Følling, I | 1 |
| Kosegawa, I | 1 |
| Katayama, S | 2 |
| Kikuchi, C | 1 |
| Kashiwabara, H | 1 |
| Negishi, K | 1 |
| Ishii, J | 1 |
| Inukai, K | 1 |
| Oka, Y | 1 |
| Granberry, MC | 1 |
| Ginsberg, H | 1 |
| Plutzky, J | 1 |
| Sobel, BE | 1 |
| Taskinen, MR | 1 |
| Valls, C | 2 |
| Spallarossa, P | 1 |
| Schiavo, M | 1 |
| Rossettin, P | 1 |
| Cordone, S | 1 |
| Olivotti, L | 1 |
| Cordera, R | 1 |
| Brunelli, C | 1 |
| Umpierrez, GE | 1 |
| Kitabchi, AE | 1 |
| Marcus, AO | 1 |
| Cohn, G | 1 |
| Valdes, G | 1 |
| Capuzzi , DM | 1 |
| Kotler, DP | 1 |
| Kent, SC | 1 |
| Legro, RS | 2 |
| Ong, K | 1 |
| Dunger, DB | 1 |
| Weisweiler, P | 1 |
| Schwandt, P | 1 |
| Fedele, D | 1 |
| Tiengo, A | 1 |
| Nosadini, R | 1 |
| Marchiori, E | 1 |
| Briani, G | 2 |
| Garotti, MC | 1 |
| Muggeo, M | 1 |
| Sirtori, CR | 1 |
| Tremoli, E | 1 |
| Sirtori, M | 1 |
| Conti, F | 1 |
| Paoletti, R | 1 |
| Shenfield, GM | 1 |
| Campbell, CJ | 1 |
| Duncan, LJ | 1 |
| Caporicci, D | 1 |
| Mori, A | 1 |
| Pepi, R | 1 |
| Lapi, E | 1 |
| Estève, B | 1 |
| Marquié, G | 2 |
| Agid, R | 2 |
| Rabast, U | 1 |
| Bär, H | 1 |
| Schönborn, J | 1 |
| Klein, W | 1 |
| Herrmann, A | 1 |
| Isnard, F | 1 |
| André, P | 1 |
| Pentikäinen, PJ | 1 |
| Voutilainen, E | 1 |
| Aro, A | 1 |
| Uusitupa, M | 1 |
| Penttilä, I | 1 |
| Vapaatalo, H | 1 |
| Crepaldi, G | 1 |
| Fellin, R | 1 |
| Baggio, G | 1 |
| Baiocchi, MR | 1 |
| Sachs, BA | 1 |
| Bardfeld, PA | 1 |
| Bodian, JE | 1 |
| Sugarman, LA | 1 |
| Hellman, L | 1 |
| Gustafson, A | 1 |
| Björntorp, P | 1 |
| Fahlén, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Fenugreek and Cumin Powder on Anthropometric Indices of Overweight and Obese Adults[NCT05966935] | 60 participants (Anticipated) | Interventional | 2023-09-15 | Not yet recruiting | |||
| Investigation of the Effect of Calisthenic Exercise Training Combined With Aerobic Exercise on Exercise Tolerance, Physical Fitness and Plasma Lipid Profile in Patients With Dyslipidemia[NCT06008912] | 24 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| A Randomized, Double-Blind, Placebo-Controlled Study of Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Subjects With Hyperinsulinemia and Elevated Waist/Hip Ratio[NCT00015691] | 105 participants | Interventional | Completed | ||||
| Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488] | Phase 4 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
26 reviews available for metformin and Hyperlipidemias
| Article | Year |
|---|---|
Intestinal lipid absorption and transport in type 2 diabetes.
Topics: Apolipoprotein B-48; Cholesterol; Chylomicron Remnants; Chylomicrons; Diabetes Mellitus, Type 2; Dip | 2022 |
New-onset diabetes mellitus after pediatric liver transplantation.
Topics: Albuminuria; Child; Cyclosporine; Diabetes Mellitus; Diabetic Retinopathy; Glucocorticoids; Humans; | 2015 |
Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.
Topics: Behavior Therapy; Bipolar Disorder; Bupropion; Cardiovascular Diseases; Diabetes Mellitus; Dopamine | 2016 |
Metabolic syndrome, diet and exercise.
Topics: Bariatric Surgery; Diet; Diet Therapy; Exercise; Exercise Therapy; Female; Humans; Hydroxymethylglut | 2016 |
Initiating insulin in patients with type 2 diabetes.
Topics: Blood Glucose; Cholesterol; Comorbidity; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, C | 2007 |
Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Insuli | 2009 |
Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a systematic review and metaanalysis.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Clinical Trials as Topic; Fibric Acids; Homocys | 2011 |
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.
Topics: Body Weight; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Co | 2003 |
Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hyperlipidemias; Hyperten | 2003 |
Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resi | 2003 |
[Insulin resistance in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Chromans; Controlled Clinical Trials as | 2003 |
Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
Topics: Albuminuria; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Hemostasis; | 2003 |
Treatment of insulin resistance in diabetes mellitus.
Topics: Anti-Inflammatory Agents; Body Weight; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; Hyp | 2004 |
Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.
Topics: Antihypertensive Agents; Comorbidity; Diabetes Mellitus; Glucosidases; Humans; Hypercholesterolemia; | 2004 |
[Treatment for coronary artery disease patients with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Coronary Artery Bypass; Coronary Artery Disease; Glucose Intolerance; Glycosid | 2005 |
The effects of metformin on cardiovascular risk factors.
Topics: Animals; Diabetes Mellitus, Type 2; Fibrinolysis; Glucose; Humans; Hyperlipidemias; Hypertension; Hy | 1995 |
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chroma | 1997 |
Insulin resistance syndrome: options for treatment.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipid | 1999 |
A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering.
Topics: Antioxidants; Blood Coagulation; Cardiovascular Diseases; Cardiovascular System; Cholesterol, LDL; C | 1999 |
Strategies for the management of diabetic dyslipidaemia.
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemia | 1999 |
Management of type 2 diabetes. Evolving strategies for treatment.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Exercise Therapy; Glycoside Hydrolase Inhibitors; Humans; Hy | 2001 |
Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
Topics: Acarbose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Human | 2000 |
Pathophysiology and treatment of the dyslipidemia of insulin resistance.
Topics: Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2001 |
Polycystic ovary syndrome in adolescents.
Topics: Adolescent; Anovulation; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Glucose Intoler | 2002 |
Polycystic ovary syndrome. Long term sequelae and management.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Contraceptives, Oral; Diabetes Mellitus, Type 2; Diag | 2002 |
[Lipid anomalies in NIDDM and insulin resistance. Role of metformin].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Insulin Resist | 1992 |
21 trials available for metformin and Hyperlipidemias
| Article | Year |
|---|---|
Antidiabetic Effect of Fenugreek Seed Powder Solution (
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic | 2019 |
Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypoglycemic Agents | 2020 |
Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Bacteria; Blood Glucose; Diabetes Mellitus, Type 2; Dr | 2018 |
Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Topics: Body Mass Index; Carbamates; China; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diab | 2014 |
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method | 2014 |
Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibit | 2016 |
Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D.
Topics: Aged; Biomarkers; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mellitus | 2015 |
Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy.
Topics: Area Under Curve; Biomarkers; Cholesterol; Fatty Acids, Nonesterified; HIV-Associated Lipodystrophy | 2011 |
Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial.
Topics: Adult; Aloe; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gels; Glyburide; Humans; Hyperc | 2012 |
Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance.
Topics: Adipose Tissue; Adult; Biomarkers; Blood Glucose; Body Composition; Body Mass Index; Cardiovascular | 2002 |
Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cohort Studies; Contraceptives, Oral; Dose-Response Relationship, Drug; | 2003 |
Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome.
Topics: Blood Glucose; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glyburide; Hu | 2003 |
Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2004 |
Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease.
Topics: Blood Glucose; Body Weight; Combined Modality Therapy; Coronary Disease; Diet; Humans; Hyperlipidemi | 1996 |
Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.
Topics: Adolescent; Adult; Blood Glucose; Female; Hirsutism; Hormones; Humans; Hyperandrogenism; Hyperinsuli | 2000 |
Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.
Topics: Aged; Aged, 80 and over; Blood Pressure; Brachial Artery; Diabetes Mellitus, Type 2; Diet, Diabetic; | 2001 |
Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.
Topics: Adult; Androgen Antagonists; Anovulation; Drug Combinations; Female; Flutamide; Humans; Hyperandroge | 2002 |
[Treatment of primary hyperlipoproteinemias type IV with different biguanides (author's transl)].
Topics: Biguanides; Buformin; Cholesterol; Female; Humans; Hyperlipidemias; Lipoproteins, VLDL; Male; Metfor | 1976 |
[Therapy of diabetes mellitus using metformin. Clinical study on 60 patients].
Topics: Body Weight; Clinical Trials as Topic; Delayed-Action Preparations; Diabetes Mellitus; Drug Therapy, | 1975 |
Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apolipoproteins; Blood Coagulation; Cholesterol; Cholest | 1990 |
Liver scan in hyperlipoproteinemia.
Topics: Adult; Aged; Aspartate Aminotransferases; Blood Protein Disorders; Blood Protein Electrophoresis; Ch | 1974 |
53 other studies available for metformin and Hyperlipidemias
| Article | Year |
|---|---|
Borapetoside E, a Clerodane Diterpenoid Extracted from Tinospora crispa, Improves Hyperglycemia and Hyperlipidemia in High-Fat-Diet-Induced Type 2 Diabetes Mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Diterpenes, Clerodane; Hyperglycemia; Hyperlipid | 2017 |
Bee venom ameliorates cardiac dysfunction in diabetic hyperlipidemic rats.
Topics: Animals; Atorvastatin; Bee Venoms; Diabetes Mellitus, Experimental; Diet, High-Fat; Heart; Hyperlipi | 2021 |
Perilla Seed Oil Alleviates Gut Dysbiosis, Intestinal Inflammation and Metabolic Disturbance in Obese-Insulin-Resistant Rats.
Topics: alpha-Linolenic Acid; Animals; Blotting, Western; Diet, High-Fat; Dysbiosis; Gastrointestinal Microb | 2021 |
Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors.
Topics: Animals; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Horse Diseases; Horses; Hype | 2023 |
Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases.
Topics: Animals; Berberine; Cricetinae; Hyperlipidemias; Lipids; Metformin; Mice; Obesity | 2023 |
Metformin inhibited Nod-like receptor protein 3 inflammasomes activation and suppressed diabetes-accelerated atherosclerosis in apoE
Topics: Adenylate Kinase; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Blood Glucose; Carrier Protein | 2019 |
A Decision-Support Software to Improve the Standard Care in Chinese Type 2 Diabetes.
Topics: Antihypertensive Agents; Aspirin; Blood Glucose; Blood Pressure; Cardiovascular Diseases; China; Dec | 2019 |
Polyherbal mixture ameliorates hyperglycemia, hyperlipidemia and histopathological changes of pancreas, kidney and liver in a rat model of type 1 diabetes.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Fe | 2021 |
Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.
Topics: Adult; Aged; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therap | 2020 |
Impact drugs targeting cardiometabolic risk on the gut microbiota.
Topics: Animals; Gastrointestinal Microbiome; Hyperlipidemias; Hypertension; Metformin | 2021 |
Metformin attenuates hyperlipidaemia-associated vascular calcification through anti-ferroptotic effects.
Topics: Animals; Humans; Hyperlipidemias; Metformin; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Rats | 2021 |
New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation.
Topics: Adolescent; Adult; Animals; Anticholesteremic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcri | 2021 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; | 2017 |
Metformin Potentiates the Benefits of Dietary Restraint: A Metabolomic Study.
Topics: Adipose Tissue; Animals; Blood Glucose; Diet; Energy Metabolism; Glucose; Homeostasis; Hyperlipidemi | 2017 |
Effect of Metformin or Chinese Herbal Formula in Patients with Type 2 Diabetes Mellitus and Hyperlipidemia: A Reassessment.
Topics: Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Hyperlipidemias; Metformin | 2018 |
Hypoglycemic and Hypolipidemic Effects of
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hyperlipidemias; Hypoglycemic A | 2019 |
In vivo pharmacodynamic and pharmacokinetic effects of metformin mediated by the gut microbiota in rats.
Topics: Administration, Oral; Animals; Blood Glucose; Catecholamine Plasma Membrane Transport Proteins; Chin | 2019 |
Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Connexins; Diabetes Mellitu | 2015 |
Hypoglycemic, lipid-lowering and metabolic regulation activities of metforminium decavanadate (H2Metf)3 [V10O28]·8H2O using hypercaloric-induced carbohydrate and lipid deregulation in Wistar rats as biological model.
Topics: Animals; Carbohydrate Metabolism; Diet, High-Fat; Glucose Metabolism Disorders; Hyperlipidemias; Hyp | 2015 |
Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.
Topics: Active Transport, Cell Nucleus; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; AM | 2015 |
Interaction between metformin and leucine in reducing hyperlipidemia and hepatic lipid accumulation in diet-induced obese mice.
Topics: Animals; Cell Line, Tumor; Diet, High-Fat; Humans; Hyperlipidemias; Leucine; Lipid Metabolism; Liver | 2015 |
Preventive effect of Caralluma fimbriata vs. Metformin against high-fat diet-induced alterations in lipid metabolism in Wistar rats.
Topics: Animals; Apocynaceae; Biomarkers; Diet, High-Fat; Disease Models, Animal; Hyperlipidemias; Hypolipid | 2016 |
Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome.
Topics: Adult; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus, Type 2; Female; Hepatitis C; Human | 2017 |
Pharmacokinetics of metformin in the rat: assessment of the effect of hyperlipidemia and evidence for its metabolism to guanylurea.
Topics: Animals; Antiporters; Catecholamine Plasma Membrane Transport Proteins; Guanidines; Hepatocytes; Hyp | 2017 |
Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; C-Reactive Protein; Diabetes Complicat | 2011 |
Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats.
Topics: Animals; Antioxidants; Aorta; Atherosclerosis; Blood Coagulation; Body Weight; Carotid Arteries; Cho | 2011 |
Should metformin be our antiglycemic agent of choice post-transplantation?
Topics: Anti-Inflammatory Agents; Anticarcinogenic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type | 2011 |
Metformin regulates hepatic lipid metabolism through activating AMP-activated protein kinase and inducing ATGL in laying hens.
Topics: Abdominal Fat; AMP-Activated Protein Kinases; Animals; Body Weight; Chickens; Eating; Enzyme Activat | 2011 |
Anti-inflammatory and anti-hyperlipidemic effect of Semecarpus anacardium in a high fat diet: STZ-induced type 2 diabetic rat model.
Topics: Animals; Anti-Inflammatory Agents; C-Reactive Protein; Diabetes Mellitus, Experimental; Diabetes Mel | 2013 |
Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance.
Topics: Adult; Blood Glucose; Body Mass Index; Drug Combinations; Female; Fluorobenzenes; Follow-Up Studies; | 2012 |
Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells.
Topics: Animals; Antioxidants; Apoptosis; Caspase 3; Cell Line; Chromans; Cytoprotection; Fatty Acids, Nones | 2012 |
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk.
Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Case-Control Studies; | 2013 |
Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
Topics: Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type | 2002 |
[Insulin resistance and its involvement in multiple risk factors associated with type 2 diabetes mellitus].
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Europe; Female; Humans; Hypercholesterolemia; Hyperli | 2002 |
Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism.
Topics: Abdomen; Adolescent; Anovulation; Body Composition; Female; Humans; Hyperandrogenism; Hyperlipidemia | 2002 |
Test and teach. Number Fifty-three. Diagnosis: Diabetes-related dyslipidaemia.
Topics: Adult; Diabetes Mellitus, Type 2; Exanthema; Female; Humans; Hyperlipidemias; Insulin; Metformin; Tr | 2004 |
The management of type II diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Metformin; Th | 2005 |
Felodipine-influenced gingival enlargement in an uncontrolled type 2 diabetic patient.
Topics: Alveolar Bone Loss; Anti-Bacterial Agents; Anticholesteremic Agents; Calcium Channel Blockers; Denta | 2005 |
Medication costs as a primary cause of nonadherence in the elderly.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Costs and C | 2006 |
Pioglitazone and metformin for increased small low-density lipoprotein in polycystic ovary syndrome: counterpoint.
Topics: Adult; Atherosclerosis; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hyperlipidemias; Metfor | 2008 |
Inhibition of carbohydrate-induced hypertriglyceridemia by metformin.
Topics: Animals; Blood Glucose; Dietary Carbohydrates; Hyperlipidemias; Insulin; Lipoproteins, VLDL; Male; M | 1984 |
[An animal model for testing hypoglycemic and hypolipidemic drugs].
Topics: Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Drugs, Chinese Herbal; Hyperlipide | 1994 |
Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance.
Topics: Aging; Animals; Blood Glucose; Blood Pressure; Blotting, Northern; Body Weight; Diabetes Mellitus, T | 1996 |
Metabolic alterations in HIV lipodystrophy. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
Topics: Acidosis; Anti-HIV Agents; Bone Diseases, Metabolic; Cost-Benefit Analysis; Glucose; Glucose Intoler | 2001 |
Hypolipidemic effects of metformin in hyperprebetalipoproteinemia.
Topics: Adult; Blood Glucose; Body Weight; Cholesterol; Diabetes Complications; Female; Glucose Tolerance Te | 1976 |
Treatment of hypertriglyceridemia with metformin. Effectiveness and analỳsis of results.
Topics: Adult; Age Factors; Blood Glucose; Body Weight; Cholesterol; Drug Evaluation; Drug Resistance; Femal | 1977 |
Hyperlipidaemia and treatment of diabetes.
Topics: Aged; Cholesterol; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Male; | 1979 |
[Effects of dimethylbiguanide (metformin) on peripheral insulin clearance and lipid biosynthesis in obese dyslipidemic subjects with and without diabetes mellitus].
Topics: Cholesterol; Diabetes Mellitus; Humans; Hyperlipidemias; Insulin; Lipids; Male; Metformin; Middle Ag | 1979 |
[NN-dimethylbiguanide attenuates the lipid disorders of rats on an atherogenic diet].
Topics: Animals; Biguanides; Cholesterol; Cholesterol, Dietary; Depression, Chemical; Diet, Atherogenic; Die | 1975 |
[Metformin in the therapy of diabetes mellitus and type IIb and IV hyperlipoproteinemia].
Topics: Adult; Aged; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Male; Metformin; Middle Aged | 1977 |
[Treatment of hyperlipoproteinemias (author's transl)].
Topics: Adolescent; Adult; Anticholesteremic Agents; Child; Cholestyramine Resin; Clofibrate; Dextrothyroxin | 1974 |
The effects of metformin on lipid-induced atherosclerosis.
Topics: Animals; Arteries; Arteriosclerosis; Blood Glucose; Cholesterol; Diet, Atherogenic; Fatty Acids, Non | 1973 |
Metformin administration in hyperlipidemic states.
Topics: Adult; Aged; Blood Glucose; Blood Protein Electrophoresis; Body Weight; Cholesterol; Electrophoresis | 1971 |